Zhongyuan Concord Yunnan Stem Cell Bank "6-1" layout of the entire biopharmaceutical industry chain

Recently, Zhongyuan Concord Yunnan Stem Cell Bank (Yunnan and Southwest Biotech Co., Ltd.) and the Chinese Academy of Sciences Kunming Institute of Zoology Primate Research Center and other institutions to carry out basic stem cell scientific research on AIDS, Alzheimer's disease, learning memory, etc. , this year will also be listed to set up stem cell and regenerative medicine expert workstation, and plans to build stem cell research and anti-aging research center in Kunming.
As a core subsidiary of Zhongyuan Concord Cell Genetic Engineering Co., Ltd., Zhongyuan Concord Yunnan Stem Cell Bank is being driven by "cell-and-gene" dual-core to "cell resource storage, gene testing and clinical diagnostic reagents, cosmetic beauty products anti-aging, tumor Biotherapy, medical and Internet plus life bank cards, pharmaceuticals and other projects in one of the "6-1" industry chain of coordinated development of a new business model, to create a covering the industry, middle and downstream life science and technology industry chain, for the benefit of the people.CAR-T cell therapy research gradually matured
This year, 9-year-old Jia Jia, after being diagnosed with leukemia patients, a second bone wear, blood pumping, chemotherapy, very painful, when transferred to the Chinese Academy of Medical Sciences in Tianjin Hematology Hospital (Hematology Research Institute), the use of CAR-T therapy to help him kill the body's leukemia cells, the disease remission, become a direct beneficiary of CAR-T therapy.
the new era of human cell therapy with the approval of two CAR-T therapies, Novarma and Kite Pharma. For Jia Jia to alleviate the pain, bring a 3-line vitality, is the Chinese Academy of Medical Sciences Hematology Hospital (Hematology Research Institute) independently developed CAR-T technology therapy, its leukemia cell lethality is obvious, has been in vivo and in vitro experiments highlighted the advantages of efficiency, research gradually mature. It is reported that 12 of the 13 patients registered in China have reached remission. Between 2014 and 2017, China Source Concord and Yunnan Stem Cell Bank successfully transplanted eight umbilical cord blood stem cells for the treatment of patients with severe thalassemia.
domestic situation, there is no car-T technology officially approved for clinical use. In order to industrialize this technology, the Hospital of Hematology (Hematology Research Institute) of the Chinese Academy of Medical Sciences has transformed the relevant technical achievements into The Chinese Source Concorde, hoping to promote its application to daily clinical trials and treatments at an early stage. Recently, the 2017 Life Sciences Innovation and Development Summit Forum hosted by Zhongyuan Concord Cell Genetic Engineering Co., Ltd. was held in Tianjin, where experts and enterprises gathered to discuss the development trend of precision medicine and cutting-edge technology, laying the foundation for the early use of CAR-T technology in clinical treatment.Research cell technology to treat AIDS At present, Zhongyuan Concord (Yunnan) Cell Bank has been working with Kunming First People's Hospital Ganmei International Hospital, Yunnan Province Infectious Diseases Specialist Hospital, the next step will be with the New Kunhua Hospital (Hematology Specialist Hospital) and other cooperation, joint stem cell research work, will be a number of third-level A hospitals in the city to establish stem cell clinical treatment centers.
It is expected that this year, stem cells and regenerative medicine doctor expert workstation will be officially established, the PLA 302 hospital infection diagnosis and treatment and research center director Wang Fusheng academician will sit in Yunnan, with Yunnan stem cell research industry to carry out immunocell technology to treat AIDS research. At the same time, the company plans to invest more than 50 million yuan in Kunming stem cell research center and anti-aging research center, is currently in location and cooperation negotiations; Recently, with the Primate Research Center of Kunming Animal Research Institute of the Chinese Academy of Sciences, the Center of Green and Health Development of Southwest Forestry University, and the Mental Health Center affiliated with Kunming Medical University, a cooperative consensus has been reached, and basic stem cell scientific research on AIDS, Alzheimer's disease, learning memory and so on will be carried out in Yunnan, forming an ecological industrial chain with integrated development of industry, science and research in Yunnan.
, reporters in the Central Source Concord Yunnan Stem Cell Bank saw that the hall walls are filled with dozens of various medals of honor and invention patent certificates. Liu Jie, general manager of Zhongyuan Concord Yunnan Stem Cell Bank, told reporters: "Of the more than 100 invention patents, such as human umbilical cord-filled stem cells and their preparation methods, there are more than 10 core technologies." "
couple happened to come to consult about cord blood storage and were changing their sterile work clothes to visit the lab. Yu Pengcheng, director of the Yunnan Stem Cell Bank Technology Center at Zhongyuan Concord, said stem cells, known as "all-in-one cells", can save lives and are consulted and visited laboratories every day. A small umbilical cord blood cell samples, from the delivery of testing to cell technology separation, and finally the cell frozen to minus 196 degrees Celsius automatic storage control system freezer, to go through dozens of cumbersome, very strict, extremely critical monitoring, research and development, production links, as long as there are microorganisms found in any link, immediately discard cells, without hesitation. To build the largest stem cell production and research base in southwest China In recent years, Zhongyuan Concord and Yunnan Stem Cell Bank have established a fine business model for the coordinated development of the "6-1" industry chain in Yunnan around the dual-core-driven development strategy of "cell-gene".
Liu Jie said that Zhongyuan Concord Cell Genetic Engineering Co., Ltd. is China's first investment in biological resources storage enterprises, is the only stem cell-based business in Shanghai and Shenzhen, dual-core-driven development of listed companies, to undertake the National Natural Science Foundation projects, to undertake two national "12th Five-Year Plan" 863 projects and 973 projects, with 26 cell libraries. In addition, it also undertakes two major construction projects: the national stem cell engineering product industrialization base and the national stem cell gene clinical transformation base.
In the storage of cell resources, the current reserves of china-source Concord Yunnan stem cell bank of about 30,000 copies, will continue to enrich the cell storage species, to achieve hematopoietic stem cells, umbilical cord-filled stem cells, placental sub-all-powerful stem cells, fat stem cells, dental stem cells, iPS stem cells and other types of stem cells storage, as well as strengthen the storage of immune cells such as a single nuclear cell; In terms of genetic testing and clinical diagnostic reagents, Zhongyuan Concord and Yunnan Stem Cell Bank vigorously develop a variety of testing projects according to market demand, forming a full-age, all-round, multi-system testing project, focusing on building early tumor screening and cardiovascular disease detection fist products; In cell therapy, through the introduction of cutting-edge scientists mastering core technology, and in cooperation with industry associations and experts in the field of China Medical Biotechnology Association, actively participate in the research of cell clinical treatment projects and promote the establishment of relevant quality standards, explore the establishment of multi-adaptive, series, multi-treatment point cell clinical treatment technology system; In the pharmaceutical business, the establishment of China Origin Pharmaceutical Co., Ltd., which is responsible for the development and declaration of cell and gene-related drugs, while strengthening cooperation with domestic and foreign research institutions, to start the upcoming or into the clinical trial phase of the project cooperation, to help the company's cell drug research and development in the forefront.
Liu Jie said that under the background of the in-depth implementation of the innovation-driven development strategy and the strategic deployment of the Healthy China 2030 Program Outline, precision medicine, with the research and transformation of stem cells, immune cells, gene testing and other technologies as the core, has become the direction of China-Source Concord's efforts. Zhongyuan Association and Yunnan Stem Cell Bank, which was supported by the Kunming Municipal Government in 2010, is currently the largest modern stem cell production and research base in southwest China, and is layout the entire biopharmaceutical industry chain of the province. (Kunming Daily)